Compare LSTA & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSTA | ICMB |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.2M |
| IPO Year | 2000 | 2013 |
| Metric | LSTA | ICMB |
|---|---|---|
| Price | $1.00 | $0.70 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.9K | 32.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 21.53% |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | $5.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.96 | $0.62 |
| 52 Week High | $5.07 | $3.12 |
| Indicator | LSTA | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 44.16 |
| Support Level | $0.99 | $0.65 |
| Resistance Level | $1.28 | $0.88 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 11.02 | 54.31 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.